< Back to Active Studies

Leuprolide +Cholinesterase Inhibition to reduce
Neurologic Decline in Alzheimer’s (LUCINDA) Study

LUCINDA Study Flyer

Inclusion Criteria

Individuals who:

    1. Diagnosis of Mild Cognitive Impairment; Alzheimer’s disease.
    2. Women ONLY, over 60 years old.
    3. Currently taking Donepezil, Memantine, Rivastigmine, Galantamine, or Namzeric (memantine/donepezil).

Exclusion Criteria

Individuals who:

    1. Frontotemporal Dementia, Parkinson’s Disease Dementia.
    2. History of epileptic seizures or epilepsy or taking medications that lower the seizure threshold (blood thinners are ok).
    3. Currently on anti-amyloid monoclonal antibody treatment.
    4. Metal implants in the head.
    5. Alcoholism or substance abuse disorder within the last 5 years.

LUCINDA is a randomized double-blind, placebo-controlled trial of Lupron and donepezil in women with mild to moderate Alzheimer’s disease.

The goal of LUCINDA trial is to learn whether an existing injectable medication Leuiprolide (Eligard®, an injectable medication) may be effective against Alzheimer’s Disease to improve activities of daily living and cognition. The trial is to determine whether Leuprolide can slow or prevent decline in cognition in women with Mild Cognitive Impairment or Alzheimer’s Disease who are also taking a cholinesterase inhibitor medication

The study is a 3-site study, investigated by University of Miami Comprehensive Center for Brain Health, Weill Cornell Medicine in NY, and University of Wisconsin. LUCINDA is supported by a grant from the National Institutes of Health.
ClinicalTrials.gov:NCT03649724
IRB APPROVED 02/20/2024

What is Leuprolide currently prescribed for? Leuprolide is approved by the FDA for treatment of prostate cancer in men, endometriosis in women and early puberty in children. It is also commonly used in women preparing for in vitro fertilization. LUCINDA aims to repurpose Leuprolide for Alzheimer’s Disease.

Who can join this study? This
study is open to women 60 years and older diagnosed with Alzheimer’s
Disease who are taking a stable
dose of the medication donepezil
(Aricept.) Participants must have a
study partner (friend or family
member) who can accompany
them to all study visits.

 

Will it cost me anything to be in
this study? No. You will be compensated for
your time and effort.

For study interest, please contact the Lucinda Study Coordinator, Adolfo Henriquez, at amh122@miami.edu. 

 

Contact Form

Go to Top of Page